



Methadone for Opioid Use Disorder

Site Applicability

PHC: All sites

Practice Level

Basic Skill: RN, RPN, LPN

Requirements

- An [Independent Double Check](#) (IDC) is required when preparing and administering oral liquid methadone.

Need to Know

- Methadone is a long-acting, synthetic [opioid agonist](#) used in the treatment of opioid use disorder.
- Most patients* that are prescribed methadone require having their daily methadone witnessed at a community pharmacy. Patients will also have an authorized methadone prescriber who may or may not be their general practitioner (GP).
- Methadone, in oral liquid form, is supplied in a concentration of **10 mg/mL** and is a [high alert medication](#) that requires an [independent double check](#) prior to administration.
- When admitted to hospital, a patient's daily methadone dose is often split into BID or TID dosing initially. This is done for safety reasons so that prescribers can assess for proper dosing based on potential drug interactions, and/or clinical status. If tolerated, split doses can then be consolidated again within several days in most cases.

*patient: refers to patient, client, or resident receiving care



Procedure

Prescriber Orders

A PowerPlan or written prescriber order will be completed by the prescriber. The medication will appear on the Medication Administration Record (MAR). The PowerPlan also contains orders for monitoring and naloxone PRN.

Only physicians who have special training and authorization can prescribe methadone at PHC. If methadone is ordered by a non-approved prescriber, pharmacy will reject the order (see image below). **Do not proceed with administration.** Contact the prescriber and/or pharmacy for clarification.

When the order is rejected it will appear on the MAR and MAW with a rejected symbol

The screenshot displays a MAR interface for 'All Medications (System)'. The 'Time View' sidebar on the left includes options: Scheduled, Unscheduled, PRN, Continuous Infusions, Future, and Discontinued Scheduled. The main table shows medication orders for 'meningococcal conjugate vaccine', 'methadone 150 mg, PO, qdaily, drug form: oral liq, start: 11-Dec-2020 11:12 PST', and 'methadone 75 mg, PO, BID, drug form: oral liq, start: 11-Dec-2020 11:16 PST'. A red 'X' is placed over the methadone order in the 12-Dec-2020 09:00 PST column. Below the MAR, a 'Pharmacy Verification' popup window is visible, stating: 'Pharmacy has rejected this order. Check all order information before administration. Continue charting?' with 'Yes' and 'No' buttons.

If attempting to document against a rejected order—a popup will appear:

Initial Assessment


Prior to administration:

- Obtain baseline respiratory rate (RR) and status (rate, depth, regularity, airway patency, and level of sedation (LOS) using the Pasero Opioid-induced Sedation Scale (POSS) [see [Appendix A](#)]. Sedation scales, such as POSS, are used to assess sedation level and can be a useful to make decisions about timing of medication interventions and when to intervene based on patients' sedation levels.
 - If patient shows signs of increased LOS (i.e., POSS of 3 or 4), **hold the dose and notify the prescriber/Addiction Medicine Consult Team (AMCT)** or most responsible physician (MRP) if after hours.
 - If patient discloses using non-prescribed opioids, assess LOS using the POSS [modified] and proceed with administering methadone if POSS is S, 1 or 2. Hold the dose if POSS is 3 or 4.
 - The POSS is designed to correlate a level of sedation with a specific intervention providing additional support in clinical decision making, and appropriate and timely escalation of care. See [Appendix A](#) for additional interventions that may be required for increased LOS.



Administration

- Verify methadone orders on the MAR and **review all the order comments**.
 - In Cerner, this may require hovering (the mouse) over the medication entry on the MAR or right clicking on the medication and selecting “Order Info...” to open order details. The order comments can be found under the “Comments” tab. Administration instructions may not be visible by just looking at the MAR.



- **Ensure at least 3 hours between all scheduled and PRN methadone doses.** Onset of effects occur 30 minutes after ingestion and average time to peak plasma concentration and peak clinical effect is 3 hours (with a range of 2-6 hours).
- Ask a colleague for an [independent double check](#) (required) prior to administration.
- Methadone must be administered directly to the patient via oral syringe.
 - *Exception:* If patient prefers methadone diluted in juice, dilution by nurse must occur at the bedside; the patient must be able to witness dose volume of methadone prior to dilution.
- Administration time of regularly scheduled methadone doses may be adjusted or rescheduled up until 23:59 on the same day as long as the dose is administered **3 hours apart** from any other scheduled or PRN doses of methadone and the patient is not too sedated (POSS of 3 or 4, see [Appendix A](#)). Nurses are not required to call AMCT when they do an adjustment within these parameters.

After midnight, there is the danger of this dose being too close to their next morning dose. Offer alternative opioid PRNs.

- *Example: A patient was off the unit for a test and missed their 09:00 daily methadone dose. The patient left the unit after the test and returned at 17:00 requesting their 09:00 dose. If the POSS score is less than 3 and they have not received any scheduled or PRN doses of methadone in the past 3 hours, it is acceptable per AMCT to reschedule and administer the 09:00 dose at 17:00.*
- If a dose is held for any reason or missed *and not able to be rescheduled*, contact prescriber/AMCT or MRP if after hours.
 - **Patients will go into withdrawal if they do not receive their methadone.** Tolerance is lost rapidly when methadone treatment is interrupted or discontinued.



Ongoing Assessment

- Monitor patient post dose for signs and symptoms of toxicity (e.g., nausea, vomiting, stomach spasms, low blood pressure, weak pulse, confusion, dizziness, cold/clammy skin). Peak toxic effects (somnolence, respiratory depression) occur around 2.5 to 4 hours after the dose. Notify methadone prescriber/AMCT if patient is drowsy and difficult to rouse 3 hours post methadone dose.
- **If patient has PRN doses of methadone** ordered, in addition to regularly scheduled dose(s), AMCT is likely trying to titrate the patient to a higher regularly scheduled dose(s).
 - **Offer the PRNs** if safe to administer based on assessment as outlined above **and 3 hours apart** from any other scheduled or PRN doses of methadone.
 - If patients receive and tolerate the PRN doses, the prescriber can consolidate/add the PRN doses to the scheduled dose the following day.

The hospital setting allows for monitoring of the patient's tolerance and sedation during titration so we are able to titrate doses faster than in community.

- In the case of suspected opioid overdose (poisoning), naloxone can be administered with or [without](#) an order. Methadone ordered within a PowerPlan for opioid use disorder will be accompanied by naloxone PRN orders for 0.1 mg or 0.4 mg IV and IM. Notify prescriber/AMCT and/or MRP if any naloxone is administered.
- Assess/ask patients about opioid withdrawal symptoms (e.g., nausea/vomiting, diaphoresis, anxiety) opioid cravings, and pain and offer PRNs accordingly.
 - Patients can receive short-acting opioids (e.g., morphine oral solution) at the same time as their methadone doses as long they are not too sedated per the POSS scale (see [Appendix A](#)).

Documentation

- Document medication administered on the MAR, including the [Independent Double Check](#) (IDC) performed prior to administration.
 - [In Cerner](#), the IDC can be signed using the 'Witnessed by' box at the time of administration at the bedside or documented after administration has occurred. After administration, this can be done by the IDC nurse by right clicking the administered dose in the MAR -> click 'Modify...' then fill in the 'Witnessed by' section and sign (see [Appendix B](#) for images).

Document pre- and post-administration LOS assessments on the POSS located in 'Interactive View and I&O' -> 'Adult Quick View' -> 'Sedation Scales' -> double click the empty box that you would like to document in and the 'Sedation Scale Used' box will appear -> select POSS (see [Appendix A](#)).

- Document any abnormal or significant findings and/or interventions in narrative charting.



Patient and Family Education

- Encourage the patient to tell you if they are experiencing pain, withdrawal symptoms, or cravings. Advise them of available PRN doses.
 - Patients may require education as to the indication for the PRN doses (e.g., to titrate and increase their regularly scheduled dose). Ten milligrams is a low dose and patients may not see the therapeutic benefit and decline the PRN.
- Advise patient to tell you if they are using non-prescribed substances while in hospital and offer education regarding harm reduction and safer substance use if appropriate.
- Offer a [Take Home Naloxone Kit](#), harm reduction supplies as appropriate and associated education.

Related Documents

- [BD-00-11-40028](#) - High-Alert Medications Policy
- [B-00-11-10125](#) - Philosophy for Care of Patients and Residents with Substance Use (Policy)
- [B-00-13-10175](#) - Dispensing Take Home Naloxone Kits to Clients at Risk of Opioid Overdose (Adults and Youth)
- [B-00-07-10096](#) - Harm Reduction and Managing Substance Use - Acute Care
- [B-00-07-10098](#) - Independent Double Check and Double Check of Medication
- [BD-00-13-40094](#)- Opioid Overdose (Suspected): Management, Including Naloxone Administration Without a Provider Order
- [BD-00-07-40094](#)– Opioid Overdose: Management of Suspected Opioid Overdoses in Community Settings (Adults & Youth) for Allied Health and Unregulated Care Providers
- BCCSU/MOH/MMHA: [A Guideline for the Clinical Management of Opioid Use Disorder - 2023 Update](#)
- Practice Standard for [Registered Nurses](#), [Registered Psychiatric Nurses](#), [Licensed Practical Nurses](#), and [Nurse Practitioners](#): Medication

Additional Education

- [UBC Continuing Professional Development \(UBC CPD\) Addiction Care and Treatment Online Course \(free\)](#)

References

- British Columbia Centre on Substance Use, BC Ministry of Health, and BC Ministry of Mental Health and Addictions. (2023, November). *A guideline for the clinical management of opioid use disorder: 2023 update..* BCCSU. <https://www.bccsu.ca/opioid-use-disorder/>
- BC Mental Health & Substance Use Services. (2023). *Opioid agonist treatment*. BCMHSUS. <http://www.bcmhsus.ca/health-professionals/clinical-professional-resources/opioid-agonist-treatment>
- Hall, K. R., & Stanley, A. Y. (2019). Literature review: Assessment of opioid-related sedation and the Pasero Opioid Sedation Scale. *Journal of PeriAnesthesia Nursing*, 34(1), 132-142. doi.org/10.1016/j.jopan.2017.12.009
- National Institutes of Health (NIH) - National Library of Medicine. (2021, November 13). *Methadone overdose*. MedlinePlus. <https://medlineplus.gov/ency/article/002679.htm>
- Pasero, C. (2009). Assessment of sedation during opioid administration for pain management. *Journal of PeriAnesthesia Nursing*, 24(3), 186-190. [doi:10.1016/j.jopan.2009.03.005](https://doi.org/10.1016/j.jopan.2009.03.005)
- Pasero, C., & McCaffery, M. (2002). Monitoring sedation: It's the key to preventing opioid-induced respiratory depression. *American Journal of Nursing*, 102(2), 67-69.

Definitions

"Opioid agonist treatment", often called "OAT", refers to the use of medication-based treatment for people who are dependent on opioids (e.g., HYDROmorphine, fentanyl). These medications (e.g., methadone) act slowly in the body, prevent withdrawal and reduce cravings for non-prescribed opioids (i.e., drugs). Opioid agonist treatment has been shown to reduce risk of drug-related harms, such as hepatitis C and HIV transmission and fatal drug poisoning (overdose), drug use and retain patients in treatment and engage in their care.



Appendix A: Pasero Opioid-induced Sedation Scale (POSS) [Modified to include interventions]

Located in Cerner PowerChart in 'Interactive View and I&O' under 'Sedation Scales' (see next page and below)

Level of Sedation (LOS)	Appropriate Action
S = Sleep, easy to arouse	Acceptable; no action necessary; may continue with opioid dose
1 = Awake and alert	Acceptable; no action necessary; may continue with opioid dose
2 = Slightly drowsy, easily aroused	Acceptable; no action necessary; may continue with opioid dose
3 = Frequently drowsy, arousable, drifts off to sleep during conversation	Unacceptable; hold opioid until improved; monitor respiratory status and sedation level closely until sedation level is stable at less than 3 and respiratory status is satisfactory; ask patient to take deep breaths every 15-30 minutes
4 = Somnolent, minimal or no response to verbal or physical stimulation	Unacceptable; hold opioid; consider administering naloxone; notify prescriber/MRP; stay with patient, stimulate, and support respiration as indicated by patient status; call Code Blue if indicated; monitor respiratory status and sedation level closely until sedation level is stable at less than 3 and respiratory status is satisfactory

Modified from: Pasero, C. (2009). Assessment of sedation during opioid administration for pain management. *Journal of PeriAnesthesia Nursing*, 24(3), 186-190. And: Hall, K. R., & Stanley, A. Y. (2019). Literature review: Assessment of opioid-related sedation and the Pasero Opioid Sedation Scale. *Journal of PeriAnesthesia Nursing*, 34(1), 132-142.



OUCH, IMSOSICK x

OUCH, IMSOSICK DOB:15-May-1960 MRN:740028298 Code Status:3-No CPR, Acute Transfer, No Intubation05-Oct-20... Process: Allergies: No Known Medication Allergies Age:63 years Enc:740000069709 PHN: n/a Dosing Wt: 60 kg (09-NOV-2023) Disease: Isolation:

Menu Patient Summary Pediatric Patient Summary Mental Health Summary Orders + Add Single Patient Task List MAR MAR Summary Interactive View and I/O Results Review Documentation + Add Documentation Filter Medication Request Histories Allergies + Add Diagnoses and Problems Appointments Calculators CareConnect Clinical Media Clinical Research Diabetes Management Workflow Form Browser Growth Chart Immunizations Lines/Tubes/Drains Summary

Adult Quick View

- NEWS (National Early Warning Score)
- VITAL SIGNS
- COVID-19 Screening
- PAIN ASSESSMENT
- Pain Modalities
- Continuous Medication Infusions
- Insulin Infusion
- Heparin Infusion
- Infusion Related Activities
- Infusion/Chemo Adverse Reaction
- Apnea/Bradycardia/Desaturation Episodes
- Mental Status/Cognition
- Sedation Scales
- Provider Notification
- Environmental Safety Management
- Activities of Daily Living
- Gastrointestinal Tubes
- Measurements
- Glucose POCT Whole Blood
- Behaviour Log
- Comfort Measures
- Transfer/Transport
- Shift Report/Handoff

Adult Systems Assessment

Adult Lines - Devices

Adult Education

Blood Product Administration

Intake And Output

Last 24 Hours

Find Item ☐ Critical ☐ High ☐ Low ☐ Abnormal ☐ Unauth ☐ Flag ☐ And ☒ Or

Result	Comments	Flag	Date	Performed By
Primary Pain Onset			11-Dec-2023 10:43 PST	
Primary Pain Location				
Primary Pain Laterality				
Primary Pain Quality				
Primary Pain Provoking				
Primary Pain Palliating				
Primary Pain Radiation Characteristics				
Primary Pain Comments				
Respiratory Rate	br/min			
Secondary Pain Site				
Additional Pain Sites				
Pain Tool Used				
Infusions Functional Activity				
Functional Activity Score				
Single Dose Functional Activity				
Functional Activity Score				
Sedation Scale				
Sedation Scale Used	Pasero Opi...			
Pasero Opioid Induced Sedation Scale				
Pasero Opioid Induced Sedation Scale	Pasero Opioid Induced Sedation Scale			
Environmental Safety Management				
Bedside Safety Check (Equipment)				
Alarms on and Reviewed				
Continuous Monitoring				
Manage Sensory Impairment				
ID Band On				
Allergy Band On				
Call Bell Within Reach				
Demos Ability-Uses Call Light w/ Success				

5=Sleep, easy to arouse
1=Awake and alert
2=Slightly drowsy, easily aroused
3=Frequently drowsy, arousable, drifts off to sleep during...
4=Somnolent, minimal or no response to verbal and physical..

This material has been prepared solely for use at Providence Health Care (PHC). PHC accepts no responsibility for use of this material by any person or organization not associated with PHC. A printed copy of this document may not reflect the current electronic version.



Appendix B: Documenting Independent Double Check (IDC) in Cerner

Charting for: GeneralMedicine-IP, Eleven

methadone
100 mg, PO, drug form: oral liq, start: 24-Apr-2021 08:00 PDT

*Performed date / time : 23-Apr-2021 1546 PDT

*Performed by : PHCTest, Nurse12

Witnessed by :

Respiratory Rate: 17 br/min

☐ Acknowledge Respiratory Rate [17 br/min, 23-April-2021 15:44 PDT](#) [Trend](#)

*methadone: 100 mg Volume: 10 ml

Diluent : <none> ml

*Route : PO Site :

Total Volume : 10 Infused Over : 0

23-Apr-2021 1400 PDT	23-Apr-2021 1500 PDT	23-Apr-2021 1600 PDT	23-Apr-2021 1700 PDT	23-Apr-2021 1800 PDT	23-Apr-2021 1900 PDT
	10				

☐ Not Given

Reason :

Comment



After administration:

Medications	27-Apr-2021 17:54 PDT	27-Apr-2021 17:53 PDT	27-Apr-2021 08:00 PDT
Scheduled			
cefTRIAxone 1,000 mg, IV, qdaily, administer over: 20 minute, order duration: 5 day, drug form: bag, start: 10/09/19 15:49:00 PDT, stop: 10/14/19 ...			
cefTRIAxone	* 1,000 mg Auth		
metFORMIN 250 mg, PO, BID with food, drug form: tab, start: 10/09/19 17:00:00 PDT			
metFORMIN	250 mg Auth (Ve		250 mg Last given: 27-Apr-2021 17:54 PDT
methadone 90 mg, PO, qdaily, drug form: oral liq, start: 27-Apr-2021 17:53 PDT			
methadone	* 90 mg Auth p...	90 mg Last given: 27-Apr-2021 17:54 PDT	
Respiratory Rate	* 12 Auth (Ver	<div>View Details...</div> <div>View Comments...</div> <div>View Order Info...</div> <div>Modify...</div> <div>Unchart...</div> <div>Forward/Refuse...</div>	
PRN			
acetaminophen 650 mg, PO, q4h, PRN pain-mild or fever, drug form: tab, start: 10/09/19 15:49:00 PDT Maximum acetaminophen 4g...	PRN 650 mg Not given within 7 days.		
acetaminophen			

Persons/Groups Consulted:

AMCT Program Physician Director

Practice Consultant, Medication Safety & Management

Medication Safety Pharmacist

General Nurse Educator - Medication Safety/Medication Management

Developed By:

Clinical Nurse Specialist, Substance Use, Urban Health Program

Nurse Educator, Urban Health Unit

Revised By:

Clinical Nurse Specialist, Substance Use, Urban Health Program

Nurse Educator, Urban Health Unit

Nurse Educator, Substance Use

Nurse Educator, Medication Safety, Medication Management

First Released Date:	February 2017
Posted Date:	10-JAN-2024
Last Revised:	10-JAN-2024
Last Reviewed:	10-JAN-2024
Approved By:	PHC
	Professional Practice Standards Committee
Owners:	PHC
	Urban Health